Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    April 2017
  1. ZONI E, Chen L, Karkampouna S, Granchi Z, et al
    CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  2. DI GIACOMO V, Tian TV, Mas A, Pecoraro M, et al
    DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  3. KO CJ, Lan SW, Lu YC, Cheng TS, et al
    Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  4. AI J, Pascal LE, Wei L, Zang Y, et al
    EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.
    Oncogene. 2017;36:2054-2065.
    PubMed     Text format     Abstract available


    March 2017
  5. RUAN D, He J, Li CF, Lee HJ, et al
    Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  6. KIM J, Jin H, Zhao JC, Yang YA, et al
    FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  7. DART AE, Worth DC, Muir G, Chandra A, et al
    The drebrin/EB3 pathway drives invasive activity in prostate cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    December 2016
  8. SHAHRIARI K, Shen F, Worrede-Mahdi A, Liu Q, et al
    Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  9. BUCAY N, Sekhon K, Yang T, Majid S, et al
    MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  10. LU W, Liu S, Li B, Xie Y, et al
    SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  11. NICKERSON ML, Das S, Im KM, Turan S, et al
    TET2 binds the androgen receptor and loss is associated with prostate cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  12. PAUL PJ, Raghu D, Chan AL, Gulati T, et al
    Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
    Oncogene. 2016 Sep 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  13. HULSURKAR M, Li Z, Zhang Y, Li X, et al
    Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1.
    Oncogene. 2016 Sep 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  14. QUEISSER A, Hagedorn S, Wang H, Schaefer T, et al
    Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    August 2016
  15. DENG X, Shao G, Zhang HT, Li C, et al
    Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Oncogene. 2016 Aug 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    July 2016
  16. CUI Y, Sun Y, Hu S, Luo J, et al
    Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  17. ZHANG Q, Liu S, Parajuli KR, Zhang W, et al
    Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  18. MARTIN PL, Yin JJ, Seng V, Casey O, et al
    Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  19. SU Q, Zhang B, Zhang L, Dang T, et al
    Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  20. CAI G, Wu D, Wang Z, Xu Z, et al
    Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization.
    Oncogene. 2016 Jun 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  21. CHAKRAVARTHI BV, Goswami MT, Pathi SS, Robinson AD, et al
    MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  22. OBINATA D, Takayama K, Fujiwara K, Suzuki T, et al
    Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  23. SELTH LA, Das R, Townley SL, Coutinho I, et al
    A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  24. ZHAO H, Lu Z, Bauzon F, Fu H, et al
    p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    February 2016
  25. WILLIAMSON M, de Winter P, Masters JR
    Plexin-B1 signalling promotes androgen receptor translocation to the nucleus.
    Oncogene. 2016;35:1066-72.
    PubMed     Text format     Abstract available


  26. RICE MA, Ishteiwy RA, Magani F, Udayakumar T, et al
    The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.
    Oncogene. 2016 Feb 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  27. ZHENG D, Gui B, Gray KP, Tinay I, et al
    Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Oncogene. 2016 Feb 15. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  28. LEE SH, Luong R, Johnson DT, Cunha GR, et al
    Androgen signaling is a confounding factor for beta-catenin-mediated prostate tumorigenesis.
    Oncogene. 2016;35:702-14.
    PubMed     Text format     Abstract available


    January 2016
  29. PARANJAPE AN, Soundararajan R, Werden SJ, Joseph R, et al
    Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    December 2015
  30. RUSCETTI M, Dadashian EL, Guo W, Quach B, et al
    HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Oncogene. 2015 Dec 7. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    November 2015
  31. BUCZEK ME, Miles AK, Green W, Johnson C, et al
    Cytoplasmic PML promotes TGF-beta-associated epithelial-mesenchymal transition and invasion in prostate cancer.
    Oncogene. 2015 Nov 9. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    October 2015
  32. WARNIER M, Roudbaraki M, Derouiche S, Delcourt P, et al
    CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis.
    Oncogene. 2015;34:5383-94.
    PubMed     Text format     Abstract available


    September 2015
  33. COARFA C, Fiskus W, Eedunuri VK, Rajapakshe K, et al
    Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
    Oncogene. 2015 Sep 14. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  34. SIU MK, Tsai YC, Chang YS, Yin JJ, et al
    Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.
    Oncogene. 2015;34:4767-76.
    PubMed     Text format     Abstract available


    August 2015
  35. FAN L, Peng G, Sahgal N, Fazli L, et al
    Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
    Oncogene. 2015 Aug 17. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  36. PUHR M, Hoefer J, Eigentler A, Dietrich D, et al
    PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
    Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  37. MAHAJAN K, Mahajan NP
    ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.
    Oncogene. 2015;34:4162-7.
    PubMed     Text format     Abstract available


    July 2015
  38. CHEN Y, Zhang Z, Yang K, Du J, et al
    Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
    Oncogene. 2015;34:3839-47.
    PubMed     Text format     Abstract available


    June 2015
  39. BJORK JK, Akerfelt M, Joutsen J, Puustinen MC, et al
    Heat-shock factor 2 is a suppressor of prostate cancer invasion.
    Oncogene. 2015 Jun 29. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  40. LIU J, You P, Chen G, Fu X, et al
    Hyperactivated FRS2alpha-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.
    Oncogene. 2015 Jun 22. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  41. BONCI D, Coppola V, Patrizii M, Addario A, et al
    A microRNA code for prostate cancer metastasis.
    Oncogene. 2015 Jun 15. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  42. PURAYIL HT, Zhang Y, Dey A, Gersey Z, et al
    Arrestin2 modulates androgen receptor activation.
    Oncogene. 2015;34:3144-51.
    PubMed     Text format     Abstract available


  43. ZHANG K, Zhao H, Ji Z, Zhang C, et al
    Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition.
    Oncogene. 2015 Jun 8. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


  44. RODRIGUEZ M, Siwko S, Zeng L, Li J, et al
    Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.
    Oncogene. 2015 Jun 1. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    May 2015
  45. JOSSON S, Gururajan M, Sung SY, Hu P, et al
    Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.
    Oncogene. 2015;34:2690-9.
    PubMed     Text format     Abstract available


    April 2015
  46. ZHAO T, Du H, Ding X, Walls K, et al
    Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-/-) mice.
    Oncogene. 2015;34:1938-48.
    PubMed     Text format     Abstract available


    March 2015
  47. NOPPARAT J, Zhang J, Lu JP, Chen YH, et al
    delta-Catenin, a Wnt/beta-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming.
    Oncogene. 2015;34:1542-52.
    PubMed     Text format     Abstract available


  48. PARISI T, Bronson RT, Lees JA
    Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancer.
    Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    July 2014
  49. YUN EJ, Baek ST, Xie D, Tseng SF, et al
    DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1.
    Oncogene. 2014 Jul 21. doi: 10.1038/onc.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: